Finance

Lists
Why is ZBIO down 4,70%?
Dive Deeper
ZBIO:NASDAQ
Zenas Biopharma Inc
25,16 US$
-4,70%
(-1,24) 1D
25,16 US$
0,00% (0,00)
After hours
Closed: 13 ოქტ, 16:00:00 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for ZBIO...
Open
26,11 US$
High
27,00 US$
Low
25,04 US$
Mkt. cap
1,64 მლრდ.
Avg. vol.
682,90 ათ.
Volume
0,00
52-wk high
44,54 US$
52-wk low
13,50 US$
EPS
-8,97 US$
Shares outstanding
65,18 მლნ.
No. of employees
167
Open
26,11 US$
High
27,00 US$
Low
25,04 US$
Mkt. cap
1,64 მლრდ.
Avg. vol.
682,90 ათ.
Volume
0,00
52-wk high
44,54 US$
52-wk low
13,50 US$
EPS
-8,97 US$
Shares outstanding
65,18 მლნ.
No. of employees
167
News stories
From web sources and news partners
Investing.com
Investing.com
·
23 საათის წინ
H.C. Wainwright reiterates Zenas Biopharma stock rating at buy
About Zenas Biopharma Inc
CEO-
Employees167
Founded2019
HeadquartersWaltham, მასაჩუსეტსი, ამერიკის შეერთებული შტატები
Sector-
Analyst ratings
Based on 5 analysts giving stock ratings to ZBIO in the past 3 months
Strong buy
Buy
4
Hold
1
Sell
0
12-month forecast
Based on 5 Wall Street analysts offering 12 month price targets for ZBIO in the last 3 months.
Highest
Current 25,16 US$
55,00 US$ (+118,60%)
Average
44,80 US$ (+78,06%)
Lowest
32,00 US$ (+27,19%)
Analyst
Recommendation
Action
Price target
Projected
Date
Unknown Analyst
Wedbush
Buy
Maintained
45,00 US$
+78,9%
10/13/2026
Matthew Caufield
H.C. Wainwright
Buy
Reiterated
44,00 US$
+74,9%
10/13/2026
Yigal Nochomovitz
Citi
Buy
Maintained
48,00 US$
+90,8%
10/12/2026
Martin Fan
Wedbush
Buy
Maintained
45,00 US$
+78,9%
09/30/2026
Judah Frommer
Morgan Stanley
Hold
Maintained
32,00 US$
+27,2%
08/17/2026
David Nierengarten
Wedbush
Buy
Maintained
45,00 US$
+78,9%
08/14/2026
Yatin Suneja
Guggenheim
Buy
Reiterated
55,00 US$
+118,6%
08/13/2026
Patrick Trucchio
H.C. Wainwright
Buy
Reiterated
44,00 US$
+74,9%
06/08/2026
Cory Kasimov
Evercore ISI
Buy
Maintained
55,00 US$
+118,6%
03/17/2026
Last report
13 აგვ. 2026
Fiscal period
Q2 2026
-1,77 US$ / -0,75 US$
-134,44%miss
Revenue / Est. (USD)
1,00 მლნ. / 15,00 მლნ.
-93,33%miss
Fiscal Q2 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
სექ. 2025
დეკ. 2025
მარ. 2026
ივნ. 2026
Revenue
-
-
-
1,00 მლნ.
Cost of goods sold
34,40 მლნ.
55,72 მლნ.
60,44 მლნ.
62,91 მლნ.
Cost of revenue
34,40 მლნ.
55,72 მლნ.
60,44 მლნ.
62,91 მლნ.
Research and development expenses
-
-
-
-
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
13,18 მლნ.
15,59 მლნ.
16,91 მლნ.
15,75 მლნ.
Operating expense
13,18 მლნ.
15,59 მლნ.
16,91 მლნ.
15,75 მლნ.
Total operating expenses
47,58 მლნ.
71,31 მლნ.
77,35 მლნ.
78,66 მლნ.
Operating income
-47,58 მლნ.
-71,31 მლნ.
-77,35 მლნ.
-77,66 მლნ.
Other non operating income
1,08 მლნ.
-7,48 მლნ.
-24,00 ათ.
16,00 ათ.
EBT including unusual items
-51,50 მლნ.
-240,34 მლნ.
-80,99 მლნ.
-111,34 მლნ.
EBT excluding unusual items
-46,50 მლნ.
-73,66 მლნ.
-80,99 მლნ.
-81,34 მლნ.
Income tax expense
-
106,00 ათ.
-
114,00 ათ.
Effective tax rate
-
-0,04%
-
-0,10%
Other operating expenses
-
-
-
-
Net income
-51,50 მლნ.
-240,44 მლნ.
-80,99 მლნ.
-111,46 მლნ.
Net profit margin
-
-
-
-11 145,60%
Earnings per share
-1,22
-1,39
-1,46
-1,77
Interest and investment income
-
12,15 მლნ.
3,02 მლნ.
6,60 მლნ.
Interest expense
-
-7,33 მლნ.
-6,63 მლნ.
-10,30 მლნ.
Net interest expenses
-
4,82 მლნ.
-3,61 მლნ.
-3,70 მლნ.
Depreciation and amortization charges
-
-
-
-
EBITDA
-47,57 მლნ.
-71,30 მლნ.
-77,34 მლნ.
-77,66 მლნ.
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google აპები